Sinopharm Group was Listed on the HKEx

Source Shanghai Securities News Sept. 24, 2009

On September 22^nd, Sinopharm Group Company Limited announced to be listed under the global offering on Hong Kong Exchanges and Clearing Limited (stock code of 01099). The offer price was determined at HK$ 16.00 per share and later closed at HK$ 18.52, rising 15.8% within the day.

As the second largest shareholder, Shanghai Fosun Pharmaceuticals got high returns on the investment of Sinopharm. Meanwhile, within the 6 years since Fosunpharma s investment in January 2003, Sinopharm has achieved 36% CAGR in revenue and 56% CAGR in net profits. It becomes a successful model of open and mutually-beneficial cooperation.

It is always Fosun s belief to continuously discover, manage and prosper. Sinopharm s success not only proves Fosun s strategy and right judgment, but also demonstrates Fosun s capabilities to grow with our partners from small size to large. Along with the society s aging process, residents income increase and the reforms of health care system, China s pharmaceutical industry will have plenty of space to grow in the next decade. Being listed on Hong Kong stock market grants a broad capital platform for Sinopharm s future development , remarked Mr. Guo Guangchang, Chairman of Fosun Group.